
    
      Eligible patients will be randomly assigned by a randomisation system in a 1:1:1 ratio to
      three group. The group A wil receive four cycles of DOX (docetaxel 60mg/m2 on day
      1,oxaliplatin 130mg/m2 on day 1 and capecitabine 1,000 mg/m2 per day on days 1 to 14,
      repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox (capecitabine 1,000
      mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as
      adjuvant therapy.The group B wil receive four cycles of Xelox (capecitabine 1,000 mg/m2 per
      day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as neoadjuvant
      therapy and four cycles of Xelox as adjuvant therapy.The group C wil receive eight cycles of
      Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1,
      repeated every 3 weeks) as adjuvant therapy.
    
  